Evenity

Chemical Nameromosozumab-aqqg
Dosage FormInjectable (subcutaneous; 105 mg/1.17 mL)
Drug ClassMonoclonal antibodies
SystemMusculoskeletal
CompanyAmgen Inc.
Approval Year2019

Indication

  • Evenity is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Last updated on 11/10/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Denosumab and romosozumab do not increase the risk of cardiovascular events in patients with primary osteoporosis: A reanalysis of the meta-analysis.2020Bone
Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials.2020Osteoporosis and Sarcopenia
Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: A network meta-analysis of survival data.2020Osteoporosis International
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis.2020Bone
Safety of romosozumab in osteoporotic men and postmenopausal women: A meta-analysis and systematic review. 2020Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: A network meta-analysis (Chongqing, China).2019Menopause
Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: A network meta-analysis.2019The Journal of Clinical Endocrinology and Metabolism
Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.2019Maturitas
Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: A meta-analysis of randomized controlled trials.2019BMC Musculoskeletal Disorders